Ms Roberta Ann Medeiros, in Pearl City, HI - Occupational Therapist

Ms Roberta Ann Medeiros, is a Occupational Therapist - Gerontology based in Pearl City, Hawaii. Ms Roberta Ann Medeiros is licensed to practice in Hawaii (license number 410) and her current practice location is 919 Lehua Ave, Pearl City, Hawaii. She can be reached at her office (for appointments etc.) via phone at (808) 455-0984.

NPI number for Ms Roberta Ann Medeiros is 1730513920 and her current mailing address is 91-328 Hoowalea Pl, Ewa Beach, Hawaii. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1730513920.

Contact Information

	Ms Roberta Ann Medeiros,
	919 Lehua Ave, Pearl City, HI 96782-3328
	(808) 455-0984
	Not Available

Healthcare Provider's Profile

Full Name	Ms Roberta Ann Medeiros
Gender	Female
Speciality	Occupational Therapist - Gerontology
Location	919 Lehua Ave, Pearl City, Hawaii
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1730513920
Provider Enumeration Date: 08/24/2013
Last Update Date: 08/24/2013

Medical Identifiers

Medical identifiers for Ms Roberta Ann Medeiros such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1730513920	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225XG0600X	Occupational Therapist - Gerontology	410 (Hawaii)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ms Roberta Ann Medeiros is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ms Roberta Ann Medeiros, 91-328 Hoowalea Pl, Ewa Beach, HI 96706-4947 Ph: () -	Ms Roberta Ann Medeiros, 919 Lehua Ave, Pearl City, HI 96782-3328 Ph: (808) 455-0984

News Archive

Notch inhibitor appears to treat breast cancer

In a novel therapeutic approach to treating breast cancer, Loyola University Medical Center researchers are reporting positive results from a clinical trial of a drug that targets tumor stem cells.

Study finds steady increase in BRCA testing among low-risk women

Discovery of the BRCA genetic mutation in the mid-90s represented a breakthrough in breast and ovarian cancer prevention. About 5-10% of breast cancer cases and 10-18% of ovarian cancer cases can be attributed to two BRCA mutations.

About 4 in 100 COVID-19 hospitalized children may develop neurological complications, a study finds

In a recently published article in The Lancet's Child & Adolescent Health, scientists have described in detail neurological and psychiatric manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children. As mentioned in the study, an estimated prevalence of infection-related neurological complications and pediatric inflammatory multisystem syndrome in hospitalized children and adolescents is about 3.8 cases per 100 patients.

Discovery Labs regains compliance with Nasdaq Minimum Bid Price Rule

Discovery Laboratories, Inc. announced today that, on January 11, 2011, a NASDAQ Listing Qualifications Panel determined that Discovery Labs has regained compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because its common stock has maintained a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on January 10, 2011.

MonoSol partner Strativa receives FDA approval for Zuplenz OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a. of Switzerland and Labtec GmbH of Germany, today announced that its partner, Strativa Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for Zuplenz® oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

Occupational Therapist in Pearl City, HI

Mrs. Kay Akiko Izumihara, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1174 Waimano Home Rd, Pearl City, HI 96782 Phone: 808-456-8090
Donnette Paishon, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 860 Fourth St, Room 150, Pearl City, HI 96782 Phone: 808-453-6964

Ms Roberta Ann Medeiros, - Occupational Therapist in Pearl City, HI